$2.72B in CY2024 Part D spend382K claims · 59K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Deutetrabenazine used for?
AUSTEDO XR ® and AUSTEDO ® are indicated in adults for the treatment of: chorea associated with Huntington’s disease [see Clinical Studies ( 14.1 )] tardive dyskinesia [see Clinical Studies ( 14.2 ....
Is there a generic for Deutetrabenazine?
No. Deutetrabenazine is brand-only with no generic equivalents currently in market.
How much does my plan pay for Deutetrabenazine?
Across 329 Part D plans, Deutetrabenazine averages $254.51/unit (NADAC). Lowest available: $83.51/unit. Highest in distribution: $499.84/unit.
Is Deutetrabenazine on the FDA shortage list?
No. Deutetrabenazine is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (12 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.